Clinical Trial Update: A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update reports results from a study of continued treatment with peginterferon alfa-2a or recombinant interferon alfa-2a in participants who …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma
• Myelogenous Leukemia
• Renal Cell Carcinoma

Drugs mentioned

• Pegasys (pegylated interferon alfa-2a)
• Roferon-A (interferon alfa-2a)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Chronic Myelogenous Leukemia, Malignant Melanoma | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2016-11-17